Program
HWK-016, MUCIN-16-targeted ADC
A development code.
Its studies are mostly in Endometrial Neoplasms, led by Whitehawk Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Whitehawk Therapeutics | 11 open or running | phase 1since Mar 9, 2026 | Mar 9, 2026 | Feb 2028phase 1 · NCT07470853 |
Also a collaborator on its studies: Catalyst Pharmaceutical Research.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 9, 2026First study: phase 1 study in Endometrial NeoplasmsFirst studyNCT07470853 · 265 planned · United States
Ahead
- Feb 2028Primary completion: phase 1 study in Endometrial NeoplasmsNCT07470853
TargetBeta
“HWK-016-101 is a Phase 1 study evaluating HWK-016, a mucin-16 (MUC-16) targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors.”study text, by rule · the study
Other programs on MUC16
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Antibody-drug Conjugate GSK5533524 | GlaxoSmithKline | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07470853Endometrial Neoplasms · United States | 1 | Recruiting | Feb 2028 | 265 |
How it is read
Names in the registry
- “HWK-016, MUCIN-16-targeted ADC”, 1 entry
Codes read as this program: HWK016.
Conditions, from the studies’ own filings
- Endometrial Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.